DUBLIN--(BUSINESS WIRE)--The "ADA-SCID - Competitive Landscape and Market Insight, 2018" report has been added to ResearchAndMarkets.com's offering.
"ADA-SCID - Competitive Landscape and Market Insight, 2018" provides comprehensive Insight about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of marketed as well as pipeline products along with the companies involved.
The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, ADA-SCID Market Evolution, and Unmet Needs. This report further provides comprehensive Insight about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.
Products covered by Phase
- Phase III and Phase II
Overview of pipeline development activities for ADA-SCID
Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Key Topics Covered:
Severe Combined Immunodeficiency (SCID)
Adenosine Deaminase - Severe Combined Immunodeficiency (ADA-SCID)
History of ADA-SCID
Pathogenesis of ADA-SCID
Inheritance pattern of ADA-SCID
Symptoms of ADA-SCID
Diagnosis of ADA-SCID
Treatment of ADA-SCID
Assumptions and Rationale
Incidence of ADA-SCID in 7MM
Prevalence of ADA-SCID in 7MM
Adagen: Leadiant Biosciences
Mechanism of Action
Advantages and Disadvantages
Safety and Efficacy
Non-integrative replicative episomal lentiviral vector technology
7MM Market Size
Product Potential Analysis
For more information about this report visit https://www.researchandmarkets.com/research/mddfd9/adenosine?w=4